153 related articles for article (PubMed ID: 38586665)
1. Mitapivat-Associated Rib Fracture in a Hemolytic Anemia Patient.
Abouelkheer Y; Ladel L; Boxer D; Shafique S
Cureus; 2024 Mar; 16(3):e55658. PubMed ID: 38586665
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Song AB; Al-Samkari H
Expert Rev Hematol; 2022 Oct; 15(10):875-885. PubMed ID: 36124781
[TBL] [Abstract][Full Text] [Related]
3. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
4. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
5. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
6. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
7. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
Zhuang-Yan A; Shirley M
Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
[TBL] [Abstract][Full Text] [Related]
8. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
10. Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.
De SK
Curr Med Chem; 2024; 31(6):683-687. PubMed ID: 37125655
[TBL] [Abstract][Full Text] [Related]
11. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 Feb; ():. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
12. Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
Grace RF
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):97-106. PubMed ID: 38066940
[TBL] [Abstract][Full Text] [Related]
13. Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis.
Matte A; Wilson AB; Gevi F; Federti E; Recchiuti A; Ferri G; Brunati AM; Pagano MA; Russo R; Leboeuf C; Janin A; Timperio AM; Iolascon A; Gremese E; Dang L; Mohandas N; Brugnara C; De Franceschi L
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37676741
[TBL] [Abstract][Full Text] [Related]
14. Pyruvate Kinase Deficiency: Current Challenges and Future Prospects.
Fattizzo B; Cavallaro F; Marcello APML; Vercellati C; Barcellini W
J Blood Med; 2022; 13():461-471. PubMed ID: 36072510
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Xu JZ; Conrey A; Frey I; Gwaabe E; Menapace LA; Tumburu L; Lundt M; Lequang T; Li Q; Glass K; Dunkelberger EB; Iyer V; Mangus H; Kung C; Dang L; Kosinski PA; Hawkins P; Jeffries N; Eaton WA; Lay Thein S
Blood; 2022 Nov; 140(19):2053-2062. PubMed ID: 35576529
[TBL] [Abstract][Full Text] [Related]
16. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
17. Confounding factors in the diagnosis and clinical course of rare congenital hemolytic anemias.
Fattizzo B; Giannotta JA; Cecchi N; Barcellini W
Orphanet J Rare Dis; 2021 Oct; 16(1):415. PubMed ID: 34627331
[TBL] [Abstract][Full Text] [Related]
18. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.
Grace RF; Bianchi P; van Beers EJ; Eber SW; Glader B; Yaish HM; Despotovic JM; Rothman JA; Sharma M; McNaull MM; Fermo E; Lezon-Geyda K; Morton DH; Neufeld EJ; Chonat S; Kollmar N; Knoll CM; Kuo K; Kwiatkowski JL; Pospíšilová D; Pastore YD; Thompson AA; Newburger PE; Ravindranath Y; Wang WC; Wlodarski MW; Wang H; Holzhauer S; Breakey VR; Kunz J; Sheth S; Rose MJ; Bradeen HA; Neu N; Guo D; Al-Sayegh H; London WB; Gallagher PG; Zanella A; Barcellini W
Blood; 2018 May; 131(20):2183-2192. PubMed ID: 29549173
[TBL] [Abstract][Full Text] [Related]
19. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme.
van Dijk MJ; de Wilde JRA; Bartels M; Kuo KHM; Glenthøj A; Rab MAE; van Beers EJ; van Wijk R
Blood Rev; 2023 Sep; 61():101103. PubMed ID: 37353463
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
